PTC Therapeutics (PTCT)

• Market cap: $4.85B
• 1 day: 0.21%
• 5 days: 7.4%
• 1 month: 34.95%
• 3 months: 19.83%
• 6 months: 13.95%
• Year to date: 33.15%
• 1 year: 86.82%
• 5 years: 25.39%
• 10 years: 61.1%
• Sector: Healthcare
• Industry: Biotechnology

About: PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Employees: 939

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

70% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $7.7M

63% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 35

37% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 81

7% more funds holding

Funds holding: 261 [Q1] → 280 (+19) [Q2]

0.91% more ownership

Funds ownership: 99.88% [Q1] → 100.79% (+0.91%) [Q2]

3% less capital invested

Capital invested by funds: $4.03B [Q1] → $3.9B (-$123M) [Q2]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 5 (-1) [Q2]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $46
• Avg. target: $74
• High target: $118

9 analyst ratings

• positive: 7 78%
• neutral: 2 22%
• negative: 0 0%

Cantor Fitzgerald Kristen Kluska	$118	Overweight Reiterated	3 Sep 2025
Wells Fargo Tiago Fauth	$73	Overweight Maintained	20 Aug 2025
Morgan Stanley Jeffrey Hung	$71	Overweight Maintained	20 Aug 2025
B of A Securities Tazeen Ahmad	$76	Buy Maintained	20 Aug 2025
RBC Capital Brian Abrahams	$63	Outperform Maintained	8 Aug 2025